Nervgen Pharma Corp.
NGEN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001751912
No open-market purchases or sales by Nervgen Pharma Corp. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $24.9M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Nervgen Pharma Corp. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1
- −1 vs. Q2 2022
- Shares held
- 3.40K
- −30.0K (−89.8%) vs. Q2 2022
- Total value
- $4.00K
- −$46.0K (−92.0%) vs. Q2 2022
- New holders
- 0
- 0 more added
- Sold out
- 1
- 0 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NGEN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 62 | $24.9M |
| Q1 2026 | 45 | $6.42M |
| Q4 2025 | 1 | $56.0K |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 1 | $5.00K |
| Q4 2023 | 1 | $6.00K |
| Q3 2023 | 1 | $4.00K |
| Q2 2023 | 1 | $4.00K |
| Q1 2023 | 1 | $4.00K |
| Q4 2022 | 1 | $4.00K |
| Q3 2022 | 1 | $4.00K |
| Q2 2022 | 2 | $50.0K |
| Q1 2022 | 2 | $48.0K |
| Q4 2021 | 2 | $70.0K |
| Q3 2021 | 1 | $12.0K |
| Q2 2021 | 1 | $25.0K |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Nervgen Pharma Corp.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FNY Investment Advisers, LLC | 3,400 | $4.00K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |